Astrazeneca Plc · LSE:AZN
Astrazeneca — 33rd J.P. Morgan Healthcare Conference 2015
11 slides from Astrazeneca's conference presentation, Jan 14, 2015
Slide 1: AstraZeneca
AstraZeneca Pascal Soriot, Executive Director, Chief Executive Officer 33rd J.P. Morgan Healthcare Conference, San Francisco 14 January 2015
Slide 2: Cautionary statement regarding forward-looking statements
Cautionary statement regarding forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: This presentation contains certain forward-looking statements
Slide 3: Completing the first phase of the journey
Completing the first phase of the journey >$45bn in 2023 2012-2014 2015-2017 2018+ Building strong Delivering on return Sustainable delivery foundations to growth and growth 3
Slide 4: Achieve scientific leadership: R&D in core therapeutic areas & across key platforms
Achieve scientific leadership: R&D in 3 core therapeutic areas & across key platforms Cardio- Respiratory/ Oncology Metabolism inflammation Infection & Vaccines Neuroscience Core TAs Opportunity-Driven Small Protein Biologics Immuno-therapies Devices molecules engineering Personalised healthcare cap
Slide 5: Achieve scientific leadership: Late-stage pipeline volume well ahead of plan
Achieve scientific leadership: Late-stage pipeline volume well ahead of plan Targeted Achieved/On track to achieve Phase III & Registration NME Phase III & Registration NME pipeline volume (#) pipeline volume (#) 14 13-15 11 9–10 8 6 6 2012 2013E 2016E 2012 2013 2014 2016E 5
Slide 6: Return to growth: Upcoming submissions drive longer-term growth
Return to growth: Upcoming submissions drive longer-term growth MEDI4736 + tremelimumab 2L SCCHN Faslodex MEDI4736 1L metastatic breast 2L SCCHN cancer Lynparza LE submission Brilinta BRCAm metastatic opportunities stroke breast cancer Lynparza saxa/dapa FDC brodalumab* BRCAm PSR type 2 diabetes pso
Slide 7: Return to growth: Oncology will become sixth growth platform
Return to growth: Oncology will become sixth growth platform Several potential oncology Oncology likely to become a key submissions 2015-2016 growth driver MEDI4736 • Several potential submissions 3L NSCLC and launches 2015-2016 MET tremelimumab • Contributes largest proportion of papillary renal me
Slide 8: Building a different shape of business
Building a different shape of business Higher probability of success, durability and profitability Increasing biologics Increasing device Increasing specialty ~50% of pipeline products care Future SC Now PC Greater durability Increasing Higher probability Greater durability profitability of success
Slide 9: Late-stage pipeline: Key news flow through 2015
Late-stage pipeline: Key news flow through 2015 Compound Indication Potential milestone brodalumab psoriasis Regulatory submission PT003 (LAMA/LABA) COPD Phase III results & regulatory submission RIA anifrolumab SLE Phase II presentation lesinurad gout Regulatory submission Brilinta prior MI (PEGASU
Slide 10: Key messages
Key messages Strategy implementation on track Late-stage pipeline progressing ahead of plans Accelerating return to growth and ambition to become a >$45bn company by 2023 Building a sustainable, durable and more profitable business Strong 2015 news flow expected 10
Slide 11: AstraZeneca
AstraZeneca Pascal Soriot, Executive Director, Chief Executive Officer 33rd J.P. Morgan Healthcare Conference, San Francisco 14 January 2015
AstraZeneca — 33rd J.P. Morgan Healthcare Conference 2015 on 6ix